anyone into these , they seem to have a very good write up and so I bought some !!! The interims are due Sept 13th worth. watching around that date. See Objective Capital.com or it may be Objective Capital .co.uk Try both

http://www.proactiveinvestors.co.uk/companies/news/46358/alliance-pharma-leaps-into-europe-after-securing-three-astrazeneca-anti-malarial-brands-46358.html
On the back of today’s news broker Numis increased its target price to 32 pence from 28 pence and revised its forecasts. It is now projecting 2013 pre-tax profits half a million more than originally forecast at £10.7 million.

UPDATE: Alliance Pharma buys stoma care product specialist
3:40 pm by Philip Whiterow and Jamie Nimmo Broker Numis upgraded the company from ‘add’ to ‘buy’ today
--adds broker comment and share price--

Speciality pharmaceutical company Alliance Pharma (LON:APH) has snapped up stoma care product specialist Opus Group for about £9.5 mln.

Opus group sells a range of products for stoma care [colostomy, ileostomy, urostomy] including skin creams and cleansers, in the UK and Ireland and generated underlying profits of £2.1 mln on sales of £3.8 mln in the year to March.

The consideration is being funded from existing cash and bank facilities. Opus’ founders Hugh Brady and John Williams will stay on for six months until David Hope, Alliance's sales and marketing director for secondary care, takes over.

“We are very pleased to complete this second major acquisition of 2012,” said John Dawson, Alliance Pharma’s chief executive.

“Opus is an exciting business with good growth potential that matches our business well in terms of customers and business drivers. It will be immediately earnings enhancing for Alliance.”

The deal will see Alliance pay £8 mln plus the net asset value of around £1.5 mln.

It will be funded out of the company’s existing revolving cash facility (RCF). The company has now spent £16.5 mln of the £20 mln available.

Alliance’s strategy is to buy up mainly prescribed and well established branded products that need little marketing.

The company owns or licenses the rights to more than 50 pharmaceutical products. Sales are mainly prescription driven and to hospitals directly or to pharmaceutical wholesalers.

Broker Numis upgraded the company from ‘add’ to ‘buy’ today, with a target price of 37 pence, up from 32 pence.

Analyst Charles Weston forecasts revenue growth of 5% per annum for Opus.

He also believes the business will require £300,000 in additional management investment, £400,000 in related support costs and £500,000 in additional interest costs on the RCF.

Weston also forecasts a 9% uplift to earnings per share in 2013, while he adds that this will increase as debt is repaid.

The news lifted the share price by 1.5 pence or 5.4% to 29.5 pence

Alliance Pharma: Investec ups target from 28p to 28.7p, hold rating kept.

Canaccord today bumped up its target price for Alliance Pharma (LON:APH) to 34 pence from 29.5 pence and reiterated its ‘buy’ rating.

The upgrade follows the pharmaceutical firm’s acquisition of Opus Healthcare, a stoma care specialist.

“At 2.4x revenues the purchase price is at the top end of the range of recent acquisitions by Alliance, but seems reasonable given the growth potential for a low risk product lines,” said the broker.

“We expect the acquisition to be earnings enhancing from completion.”

been looking at these for a few days but not bought yet, chart says wait a bit.,.
">

Tipped in this weeks share mag. There could be likely earnings upgrades after last weeks acquisition of Opus.

Alliance Pharma gets more ammo for acquisition drive
1:16 pm by Philip WhiterowAlliance has £13.5mln to spend following the latest injection of funds.

Alliance Pharma's (LON:APH) expansion of its acquisition fund is a key development for the specialist pharmaceutical company, according to broker Numis.

The group today announced an additional £10mln facility with Lloyds Banking Group, taking the total facility available to the group to make purchases up to £30mln.

Alliance has used £16.5mln of the facility and has £13.5mln to spend following the latest injection of funds.

Numis said that management has executed on 23 deals over the last 14 years and continually reiterates the strength of its M&A pipeline.

If the £13.5mln was fully deployed on acquisitions through 2013 at the historical average 3 times gross profit, the broker sees up to 30% upside to its 2014 profit forecasts.

“P/E multiples in the speciality pharma/generics peer group have expanded one point to 12x over the last couple of months - we therefore increase our price target to 42p, from 37p and reiterate our buy rating,” said Numis.

Alliance also said profits will beat market forecasts for the year just ended after very strong sales of skin and eczema emollient Hydromol.

“As a result of a stronger than expected gross margin rate, pre-tax profits are expected to be slightly ahead of current market expectations,“ the specialist pharmaceutical group said.

Total revenues in 2012 will be £44.9mln, compared to £46mln in the previous year.

Sales were hit by Sanofi Pasteur’s temporary suspension of the manufacture of Immucyst in June, but Hydromol’s record performance offset some of the impact. Hydromol sales grew by 29% or £1.1 mln to £4.7 mln.

Last year’s acquisitions, Opus Group and three anti-malarial brands, performed as expected, Alliance Pharma said.

Numis also raised its 2012 profit forecast to £10.5mln, from £10.2mln, following the update.

The company’s business model is to acquire the rights to established niche pharmaceutical products. It now owns or licenses the rights to more than 60 products.

Shares rose by 4% to 33.5p.

Had a good run since Aug, sold my holding.

Gone long this morning.

Results next month looks an interesting company.

APH

Not far off breaking out.

BUY placed on it by SCSW tip sheet
this weekend.

Personaly Im looking for a bolt on
before results on 21st of March...

see historical item below.....

Alliance Pharma gets more ammo for acquisition drive
15th Jan 2013, 1:16 pm by Philip Whiterow

Alliance has £13.5mln to spend following the latest injection of funds. Alliance Pharma's (LON:APH) expansion of its acquisition fund is a key development for the specialist pharmaceutical company, according to broker Numis.

The group today announced an additional £10mln facility with Lloyds Banking Group, taking the total facility available to the group to make purchases up to £30mln.

Alliance has used £16.5mln of the facility and has £13.5mln to spend following the latest injection of funds.

Numis said that management has executed on 23 deals over the last 14 years and continually reiterates the strength of its M&A pipeline.

If the £13.5mln was fully deployed on acquisitions through 2013 at the historical average 3 times gross profit, the broker sees up to 30% upside to its 2014 profit forecasts.

“P/E multiples in the speciality pharma/generics peer group have expanded one point to 12x over the last couple of months - we therefore increase our price target to 42p, from 37p and reiterate our buy rating,” said Numis.

Alliance also said profits will beat market forecasts for the year just ended after very strong sales of skin and eczema emollient Hydromol.

“As a result of a stronger than expected gross margin rate, pre-tax profits are expected to be slightly ahead of current market expectations,“ the specialist pharmaceutical group said.

Total revenues in 2012 will be £44.9mln, compared to £46mln in the previous year.

Sales were hit by Sanofi Pasteur’s temporary suspension of the manufacture of Immucyst in June, but Hydromol’s record performance offset some of the impact. Hydromol sales grew by 29% or £1.1 mln to £4.7 mln.

Last year’s acquisitions, Opus Group and three anti-malarial brands, performed as expected, Alliance Pharma said.

Numis also raised its 2012 profit forecast to £10.5mln, from £10.2mln, following the update.

The company’s business model is to acquire the rights to established niche pharmaceutical products. It now owns or licenses the rights to more than 60 products.

Shares rose by 4% to 33.5p.

http://www.proactiveinvestors.co.uk/companies/news/52444/alliance-pharma-gets-more-ammo-for-acquisition-drive-52444.html

APH Alliance Pharma. Results on the 21st of this month. Thursday. Think profits will beat broker forecasts.. just added.

Results later this morning.

Solid looking results.

Finncap were looking for EPS of 3p
this year 2012 and 3.6p year ending
2013 therefore company are 1 year ahead
on expected profits.

Dividend risen aswel 10%...excelent news.

http://www.investegate.co.uk/alliance-pharma-plc--aph-/rns/preliminary-results/201303210700265097A/

Alliance Pharma: interesting little acquisition of a product that could be in growing demand from the ageing population - See more at: http://www.investorschampion.com/blog

RNS:- "Higher Costs" seems to have knocked the sp today ( now 81-p ), but it is still a solid Co. IMHO. - Though it may be some time before the 1% yield improves.

being watching this little thing for a while, pretty solid numbers, strong free cash flow, 'higher costs' just a 3%-off problem, current PE15 means I got some space here, at half of a book value this thing let me sleep well :) got few bits before close at 64.9

Got out flat, I've found better place